On Monday, Raymond James issued a downgrade for Disc Medicine (NASDAQ:IRON) from Strong Buy to Outperform, simultaneously lowering the stock price target to $40 from the previous $75. The adjustment comes in response to uncertainties surrounding the future of bitopertin in erythropoietic protoporphyria (EPP), leading to an anticipated decline in share value by at least 40% today.
